Abstract:Piperine (PIP), the major alkaloid component from Piper longum L. and Piper nigrum L., could enhance the bioavailabilities of other drugs including rosuvastatin, peurarin and docetaxel (DOX) via inhibition of CYP3A and P-glycoprotein activity. Nevertheless, the effect of such drug combination usage on the in vivo exposure of PIP has not been investigated due to lack of assay for the simultaneous determination of PIP and other drugs such as DOX. Besides, the reported pharmacokinetics of PIP varied a lot without appropriate bioavailability determined from the same dose. In the current study, an LC/MS/MS method has been developed to simultaneously determine the plasma concentrations of PIP and DOX and further applied to investigate the pharmacokinetics properties of PIP after oral and intravenous administrations as well as the pharmacokinetics interactions between PIP and DOX after their co-administration. A simple protein precipitation method was employed for plasma sample treatment by adding a mixture of methanol and acetonitrile (1:1, v/v) with glibenclamide as internal standard (IS). The LC/MS/MS system consisted of Agilent 6430 series LC pumps and auto-sampler. The chromatographic separation was carried out in 15min on a Waters C18 column (150×3.9mm i.d., 4μm) with a mobile phase containing 0.2% formic acid and acetonitrile (1:1, v/v) at a flow rate of 0.4ml/min. The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with precursor-to-product ion transitions at m/z 286.1→201.1 for PIP, m/z 830.3→548.9 for DOX and m/z 494.2→369.0 for IS. The method demonstrated good linearity for both PIP and DOX over the concentration range of 2.5-1280ng/ml with LLOD at 2.5ng/ml. The intra-day and inter-day precisions were less than 13.34% and relative error (R.E.) representing accuracy was in the range of -11.38 to 3.15%. The recoveries of PIP, DOX and IS were above 75% and there was no matrix effect. PIP and DOX exhibited good stabilities under various conditions. PIP was administrated via intravenous bolus at 3.5mg/kg and via oral administration at 35mg/kg and 3.5mg/kg, while DOX was intravenously administrated at 7mg/kg to Sprague-Daley rats. The plasma concentrations of PIP and DOX were determined using the above developed and validated method. At the dose of 3.5mg/kg, the bioavailability of PIP was calculated to be 25.36%. Its AUC0→t was unproportionally increased with doses, indicating a potential non-linear pharmacokinetics profile of PIP. It was found that the AUC0→t and C0 of DOX and t1/2 of PIP were significantly increased after their combination use, suggesting potential enhanced bioavailability of not only DOX but also PIP, which may lead to the overall enhanced pharmacological effects.

Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS.

Loperamide, an Antidiarrheal Agent, Induces Apoptosis and DNA Damage in Leukemia Cells.

Opioid Analgesics-Related Pharmacokinetic Drug Interactions: from the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management

Effect of Apatinib on the Pharmacokinetics of Tramadol and O-desmethyltramadol in Rats.

Functional Characteristics Of Cyp3a4 Allelic Variants On The Metabolism Of Loperamide In Vitro

Non-linear Pharmacokinetics of Piperine and Its Herb-Drug Interactions with Docetaxel in Sprague-Dawley Rats.

Effects on CYP2D6 by the Single Use of Ampicillin and Shuanghuanglian or Combination of Both

Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity

Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism

Evaluating the impact of loperamide on irinotecan-induced adverse events: a disproportionality analysis of data from the World Health Organization pharmacovigilance database (VigiBase)

The Impacts of CYP3A4 Genetic Polymorphism and Drug Interactions on the Metabolism of Lurasidone

The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro.

Subacute toxicity evaluations of LPM3480392 in rats, a full μ-opioid receptor biased agonist

Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment

Loperamide, an antidiarrhea drug, has antitumor activity by inducing cell apoptosis

Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy

Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial

Multiple Circulating Alkaloids and Saponins from Intravenous Kang-Ai Injection Inhibit Human Cytochrome P450 and UDP-glucuronosyltransferase Isozymes: Potential Drug-Drug Interactions

Loperamide blocks high-voltage-activated calcium channels and N-methyl-D-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurons

Quantification of Axitinib After Oral and Intravenous Administration in Rats by UPLC-MS/MS: Application to the Pharmacokinetic Study

Effect of Ginkgo tablets on the pharmacokinetics of metoprolol in rats: liquid chromatography-tandem mass spectrometry-based study